Gary Gibson is a tenured Professor of Neuroscience at Weill Cornell Medicine and serves as Lab Director at the Burke Neurological Institute . He leads the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration , focusing on age-related neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease . Educational background: Ph.D. in Physiology (Biochemistry/Neuroscience), Cornell University B.S. in Zoology and Chemistry, University of Wyoming His research investigates how mitochondrial dysfunction , reduced glucose metabolism , and oxidative stress contribute to neurodegeneration. He explores therapeutic interventions targeting these mechanisms, including benfotiamine for improving thiamine levels and modulating post-translational modifications of mitochondrial enzymes like the α-ketoglutarate dehydrogenase complex (KGDHC) . These studies integrate human autopsy samples, genetically modified cells , and transgenic mouse models to test hypotheses about calcium dysregulation, free radical damage, and inflammatory cascades. Recent publications highlight his work on mitochondrial enzyme plasticity , nutritional metabolism in dementia, and benfotiamine's neuroprotective effects in clinical trials. He has secured continuous NIH funding (Grant R01AG043679) and holds three U.S. patents . Dr. Gibson serves on editorial boards for Neurochemical Research , Neurochemical International , and Journal of Neurochemistry , and has mentored undergraduate students and postdoctoral researchers .
